Literature DB >> 23420906

A new strategy for the prevention of Clostridium difficile infection.

Amber Howerton1, Manomita Patra, Ernesto Abel-Santos.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) is a leading cause of antibiotic-associated diarrhea. The infective form of C. difficile is the spore, but the vegetative bacterium causes the disease. Because C. difficile spore germination is required for symptomatic infection, antigermination approaches could lead to the prevention of CDI. We recently reported that CamSA, a bile salt analog, inhibits C. difficile spore germination in vitro.
METHODS: Mice infected with massive inocula of C. difficile spores were treated with different concentrations of CamSA and monitored for CDI signs. C. difficile spore and vegetative cells were counted in feces from infected mice.
RESULTS: A single 50-mg/kg dose of CamSA prevented CDI in mice without any observable toxicity. Lower CamSA doses resulted in delayed CDI onset and less severe signs of disease. Ingested C. difficile spores were quantitatively recovered from feces of CamSA-protected mice.
CONCLUSIONS: Our results support a mechanism whereby the antigermination effect of CamSA is responsible for preventing CDI signs. This approach represents a new paradigm in CDI treatment. Instead of further compromising the microbiota of CDI patients with strong antibiotics, antigermination therapy could serve as a microbiota surrogate to curtail C. difficile colonization of antibiotic-treated patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420906     DOI: 10.1093/infdis/jit068

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination.

Authors:  Kristen L Stoltz; Raymond Erickson; Christopher Staley; Alexa R Weingarden; Erin Romens; Clifford J Steer; Alexander Khoruts; Michael J Sadowsky; Peter I Dosa
Journal:  J Med Chem       Date:  2017-04-12       Impact factor: 7.446

Review 3.  Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.

Authors:  Jenessa A Winston; Casey M Theriot
Journal:  Anaerobe       Date:  2016-05-07       Impact factor: 3.331

4.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

Review 5.  Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.

Authors:  Robert A Britton; Vincent B Young
Journal:  Gastroenterology       Date:  2014-02-04       Impact factor: 22.682

Review 6.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

7.  Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.

Authors:  Zhi Lv; Guoli Peng; Weihua Liu; Hufeng Xu; JianRong Su
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 8.  Clostridium difficile spore biology: sporulation, germination, and spore structural proteins.

Authors:  Daniel Paredes-Sabja; Aimee Shen; Joseph A Sorg
Journal:  Trends Microbiol       Date:  2014-05-07       Impact factor: 17.079

Review 9.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014

Review 10.  Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Nancy Fu; Titus Wong
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.